Drug intelligence / Profile preview

GPC3 CAR-T

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Portal Vein Injection, Hepatic Arterial Infusion, Intracavitary, Tail Vein Injection

Overview

GPC3 CAR-T is a type of Chimeric Antigen Receptor (CAR) T cell therapy designed to target Glypican 3 (GPC3) expressing tumor cells. It is being investigated as a potential treatment for solid tumors, particularly hepatocellular carcinoma (HCC), where GPC3 is often highly expressed. The CAR-T cells are engineered to recognize and be activated by GPC3 on tumor cells, leading to antitumor activity. Studies have shown its efficacy in preclinical models against GPC3-expressing tumor cells.

Other names: anti-GPC3 CAR-T cellsanti-GPC-3 CAR-T cellsanti-GPC 3 CAR-T cells

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on GPC3 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPC3 CAR-T.

Explore the full profile